Drug treatment for metabolic dysfunction-associated steatotic liver disease:Progress and direction  

作　　者：Da Zhou Jiangao Fan 

机构地区：[1]Department of Gastroenterology and Hepatology,Zhongshan Hospital of Fudan University,Shanghai 200032,China [2]Shanghai Institute of Liver Diseases,Fudan University Shanghai Medical College,Shanghai 200032,China [3]Department of Gastroenterology,Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China [4]Shanghai Key Lab of Pediatric Gastroenterology and Nutrition,Shanghai 200092,China.

出　　处：《Chinese Medical Journal》2024年第22期2687-2696,共10页中华医学杂志(英文版)

基　　金：supported by grants from the National Science and Technology Major Project of China(No.2023ZD0508700);the National Natural Science Foundation of China(No.82170593).

摘　　要：Metabolic dysfunction-associated steatotic liver disease(MASLD),also called non-alcoholic fatty liver disease,is the most epidemic chronic liver disease worldwide.Metabolic dysfunction-associated steatohepatitis(MASH)is the critical stage of MASLD,and early diagnosis and treatment of MASH are crucial for reducing the incidence of intrahepatic and extrahepatic complications.So far,pharmacotherapeutics for the treatment of MASH are still a major challenge,because of the complexity of the pathogenesis and heterogeneity of MASH.Many agents under investigation have shown impressive therapeutic effects by targeting different key pathways,including the attenuation of steatohepatitis or fibrosis or both.It is notable that thyroid hormone receptor-βagonist,resmetirom has become the first officially approved drug for treating MASH with fibrosis.Other agents such as peroxisome proliferator-activated receptor agonists,glucagon-like peptide-1 analogs,and fibroblast growth factor 21 analogs are awaiting approval.This review focuses on the current status of drug therapy for MASH and summarizes the latest results of new medications that have completed phase 2 or 3 clinical trials,and presents the future directions and difficulties of new drug research for MASH.

关 键 词：Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatohepatitis Non-alcoholic steatohepatitis Non-alcoholic fatty liver disease PHARMACOTHERAPY Clinical trial 

分 类 号：R57[医药卫生—消化系统]